- Home
- SKYE vs SOL Comparison
SKYE vs SOL Comparison
Compare SKYE & SOL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- SOL
- Stock Information
- Founded
- SKYE 2012
- SOL 2005
- Country
- SKYE United States
- SOL United States
- Employees
- SKYE N/A
- SOL N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- SOL Semiconductors
- Sector
- SKYE Health Care
- SOL Technology
- Exchange
- SKYE Nasdaq
- SOL Nasdaq
- Market Cap
- SKYE 80.7M
- SOL 84.6M
- IPO Year
- SKYE N/A
- SOL 2008
- Fundamental
- Price
- SKYE $2.30
- SOL $1.67
- Analyst Decision
- SKYE Buy
- SOL Buy
- Analyst Count
- SKYE 6
- SOL 3
- Target Price
- SKYE $16.60
- SOL $3.50
- AVG Volume (30 Days)
- SKYE 237.9K
- SOL 146.1K
- Earning Date
- SKYE 05-08-2025
- SOL 05-14-2025
- Dividend Yield
- SKYE N/A
- SOL N/A
- EPS Growth
- SKYE N/A
- SOL N/A
- EPS
- SKYE N/A
- SOL N/A
- Revenue
- SKYE N/A
- SOL $85,621,000.00
- Revenue This Year
- SKYE N/A
- SOL N/A
- Revenue Next Year
- SKYE N/A
- SOL $45.37
- P/E Ratio
- SKYE N/A
- SOL N/A
- Revenue Growth
- SKYE N/A
- SOL N/A
- 52 Week Low
- SKYE $1.14
- SOL $1.04
- 52 Week High
- SKYE $12.11
- SOL $3.00
- Technical
- Relative Strength Index (RSI)
- SKYE 57.25
- SOL 55.54
- Support Level
- SKYE $1.96
- SOL $1.63
- Resistance Level
- SKYE $2.28
- SOL $1.87
- Average True Range (ATR)
- SKYE 0.23
- SOL 0.11
- MACD
- SKYE 0.02
- SOL 0.01
- Stochastic Oscillator
- SKYE 86.89
- SOL 47.82
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About SOL Emeren Group Ltd each representing 10 shares
Emeren Group Ltd is a renewable energy producer. Its portfolio consists of solar projects and Independent Power Producer (IPP) assets, and it also has global Battery Energy Storage System (BESS) capacity. The group specializes in the solar project lifecycle, development, and from construction to financing. It has three reportable segments; Solar power project development, EPC services, and Electricity generation. The company generates maximum revenue from Poland.